Immunoregulatory networks in human Chagas disease

Parasite Immunology

Volumn 36, Issue 8, 2014, Pages 377-387

  Dutra, W O ^a,b   Menezes, C A S ^a,b   Magalhaes L M D ^a,b   Gollob, K J ^b,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Instituto Nacional de Ciência e Tecnologia Doenças Tropicais INCT DT   (Brazil)

^c Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

Chagas disease; Cytokines; Immunoregulation; Neuroendocrine; Pathology; Trypanosoma cruzi

Indexed keywords

CYTOKINE;

ANIMAL; CHAGAS DISEASE; GENE EXPRESSION REGULATION; GENETICS; HOST PARASITE INTERACTION; HUMAN; IMMUNOLOGY; IMMUNOREGULATION; METABOLISM; NEUROENDOCRINE; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TRYPANOSOMA CRUZI;

CHAGAS DISEASE; CYTOKINES; IMMUNOREGULATION; NEUROENDOCRINE; PATHOLOGY; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; CYTOKINES; GENE EXPRESSION REGULATION; HOST-PARASITE INTERACTIONS; HUMANS; SIGNAL TRANSDUCTION; TRYPANOSOMA CRUZI;

EID: 84908466372     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12107     Document Type: Review

References (80)

1. Moncayo A & Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 2006; 100: 663-677.
2. Bern C, Kjos S, Yabsley MJ & Montgomery SP. Trypanosoma cruzi and Chagas' disease in the United States. Clin Microbiol Rev 2011; 24: 655-681.
3. Coura JR & Vinas PA. Chagas disease: a new worldwide challenge. Nature 2010; 465: S6-S7.
4. Sosa-Estani S & Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 2006; 19: 583-587.
5. Rassi A, Luquetti AO, Rassi A Jr, et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg 2007; 76: 58-61.
6. Rocha MO, Teixeira MM & Ribeiro AL. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 2007; 5: 727-743.
7. Brisse S, Henriksson J, Barnabe C, et al. Evidence for genetic exchange and hybridization in Trypanosoma cruzi based on nucleotide sequences and molecular karyotype. Infect Genet Evol 2003; 2: 173-183.
8. Zingales B, Stolf BS, Souto RP, Fernandes O & Briones MR. Epidemiology, biochemistry and evolution of Trypanosoma cruzi lineages based on ribosomal RNA sequences. Mem Inst Oswaldo Cruz 1999; 94(Suppl. 1): 159-164.
9. Zingales B, Andrade SG, Briones MR, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 2009; 104: 1051-1054.
10. Tibayrenc M. Genetic epidemiology of parasitic protozoa and other infectious agents: the need for an integrated approach. Int J Parasitol 1998; 28: 85-104.
11. Tibayrenc M. Genetic subdivisions within Trypanosoma cruzi (Discrete Typing Units) and their relevance for molecular epidemiology and experimental evolution. Kinetoplastid Biol Dis 2003; 2: 12.
12. Brisse S, Dujardin JC & Tibayrenc M. Identification of six Trypanosoma cruzi lineages by sequence-characterised amplified region markers. Mol Biochem Parasitol 2000; 111: 95-105.
13. Laurent JP, Barnabe C, Quesney V, Noel S & Tibayrenc M. Impact of clonal evolution on the biological diversity of Trypanosoma cruzi. Parasitology 1997; 114(Pt 3): 213-218.
14. Revollo S, Oury B, Laurent JP, et al. Trypanosoma cruzi: impact of clonal evolution of the parasite on its biological and medical properties. Exp Parasitol 1998; 89: 30-39.
15. de Lana M, da Silveira Pinto A, Barnabe C, Quesney V, Noel S & Tibayrenc M. Trypanosoma cruzi: compared vectorial transmissibility of three major clonal genotypes by Triatoma infestans. Exp Parasitol 1998; 90: 20-25.
16. Pinto AS, de Lana M, Bastrenta B, et al. Compared vectorial transmissibility of pure and mixed clonal genotypes of Trypanosoma cruzi in Triatoma infestans. Parasitol Res 1998; 84: 348-353.
17. Brisse S, Barnabe C & Tibayrenc M. Identification of six Trypanosoma cruzi phylogenetic lineages by random amplified polymorphic DNA and multilocus enzyme electrophoresis. Int J Parasitol 2000; 30: 35-44.
18. Brisse S, Verhoef J & Tibayrenc M. Characterisation of large and small subunit rRNA and mini-exon genes further supports the distinction of six Trypanosoma cruzi lineages. Int J Parasitol 2001; 31: 1218-1226.
19. Di Noia JM, Buscaglia CA, De Marchi CR, Almeida IC & Frasch AC. A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas' disease is due to a single parasite lineage. J Exp Med 2002; 195: 401-413.
20. Macedo AM, Machado CR, Oliveira RP & Pena SD. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of chagas disease. Mem Inst Oswaldo Cruz 2004; 99: 1-12.
21. Steindel M, Kramer Pacheco L, Scholl D, et al. Characterization of Trypanosoma cruzi isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil. Diagn Microbiol Infect Dis 2008; 60: 25-32.
22. Anez N, Crisante G, da Silva FM, et al. Predominance of lineage I among Trypanosoma cruzi isolates from Venezuelan patients with different clinical profiles of acute Chagas' disease. Trop Med Int Health 2004; 9: 1319-1326.
23. Miles MA, Cedillos RA, Povoa MM, de Souza AA, Prata A & Macedo V. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? Lancet 1981; 1: 1338-1340.
24. Breniere SF, Bosseno MF, Noireau F, et al. Integrate study of a Bolivian population infected by Trypanosoma cruzi, the agent of Chagas disease. Mem Inst Oswaldo Cruz 2002; 97: 289-295.
25. Zingales B, Miles MA, Campbell DA, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol 2012; 12: 240-253.
26. Andrade LO, Galvao LM, Meirelles Mde N, Chiari E, Pena SD & Macedo AM. Differential tissue tropism of Trypanosoma cruzi strains: an in vitro study. Mem Inst Oswaldo Cruz 2010; 105: 834-837.
27. Pena DA, Eger I, Nogueira L, et al. Selection of TcII Trypanosoma cruzi population following macrophage infection. J Infect Dis 2011; 204: 478-486.
28. Macedo AM & Pena SD. Genetic variability of Trypanosoma cruzi: implications for the pathogenesis of Chagas disease. Parasitol Today 1998; 14: 119-124.
29. Franco DJ, Vago AR, Chiari E, Meira FC, Galvao LM & Machado CR. Trypanosoma cruzi: mixture of two populations can modify virulence and tissue tropism in rat. Exp Parasitol 2003; 104: 54-61.
30. Freitas JM, Andrade LO, Pires SF, et al. The MHC gene region of murine hosts influences the differential tissue tropism of infecting Trypanosoma cruzi strains. PLoS ONE 2009; 4: e5113.
31. Cruz-Robles D, Reyes PA, Monteon-Padilla VM, Ortiz-Muniz AR & Vargas-Alarcon G. MHC class I and class II genes in Mexican patients with Chagas disease. Hum Immunol 2004; 65: 60-65.
32. Menezes CA, Sullivan AK, Falta MT, et al. Highly conserved CDR3 region in circulating CD4(+)Vbeta5(+) T cells may be associated with cytotoxic activity in Chagas disease. Clin Exp Immunol 2012; 169: 109-118.
33. Vago AR, Andrade LO, Leite AA, et al. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am J Pathol. 2000; 156: 1805-1809.
34. D'Avila DA, Macedo AM, Valadares HM, et al. Probing population dynamics of Trypanosoma cruzi during progression of the chronic phase in chagasic patients. J Clin Microbiol 2009; 47: 1718-1725.
35. del Puerto R, Nishizawa JE, Kikuchi M, et al. Lineage analysis of circulating Trypanosoma cruzi parasites and their association with clinical forms of Chagas disease in Bolivia. PLoS Negl Trop Dis 2010; 4: e687.
36. Burgos JM, Risso MG, Breniere SF, Barnabe C, Campetella O & Leguizamon MS. Differential distribution of genes encoding the virulence factor trans-sialidase along Trypanosoma cruzi Discrete typing units. PLoS ONE 2013; 8: e58967.
37. Martin DL, Weatherly DB, Laucella SA, et al. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2: e77.
38. Todeschini AR, Nunes MP, Pires RS, et al. Costimulation of host T lymphocytes by a trypanosomal trans-sialidase: involvement of CD43 signaling. J Immunol 2002; 168: 5192-5198.
39. Guedes PM, Veloso VM, Caliari MV, et al. Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in Beagle dogs. Mem Inst Oswaldo Cruz 2007; 102: 141-147.
40. Rodrigues AA, Saosa JS, da Silva GK, et al. IFN-gamma plays a unique role in protection against low virulent Trypanosoma cruzi strain. PLoS Negl Trop Dis 2012; 6: e1598.
41. Krettli AU. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives. Mem Inst Oswaldo Cruz 2009; 104(Suppl. 1): 142-151.
42. Teixeira MM, Gazzinelli RT & Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 2002; 18: 262-265.
43. Silva JS, Vespa GN, Cardoso MA, Aliberti JC & Cunha FQ. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 1995; 63: 4862-4867.
44. Marques J, Mendoza I, Noya B, Acquatella H, Palacios I & Marques-Mejias M. ECG manifestations of the biggest outbreak of Chagas disease due to oral Infection in Latin-America. Arq Bras Cardiol 2013; 101: 249-254.
45. Souza PE, Rocha MO, Rocha-Vieira E, et al. Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun 2004; 72: 5283-5291.
46. Sathler-Avelar R, Lemos EM, Reis DD, et al. Phenotypic features of peripheral blood leucocytes during early stages of human infection with Trypanosoma cruzi. Scand J Immunol 2003; 58: 655-663.
47. Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A, et al. Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol 2008; 68: 516-525.
48. Dutra WO, Colley DG, Pinto-Dias JC, et al. Self and nonself stimulatory molecules induce preferential expansion of CD5+ B cells or activated T cells of chagasic patients, respectively. Scand J Immunol 2000; 51: 91-97.
49. Araujo FF, Gomes JA, Rocha MO, et al. Potential role of CD4+CD25HIGH regulatory T cells in morbidity in Chagas disease. Front Biosci 2007; 12: 2797-2806.
50. de Araujo FF, Correa-Oliveira R, Rocha MO, et al. Foxp3+CD25(high) CD4+ regulatory T cells from indeterminate patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity. Immunobiology 2012; 217: 768-777.
51. Magalhaes LM, Villani FN, Nunes Mdo C, Gollob KJ, Rocha MO & Dutra WO. High interleukin 17 expression is correlated with better cardiac function in human Chagas disease. J Infect Dis 2013; 207: 661-665.
52. Miyazaki Y, Hamano S, Wang S, Shimanoe Y, Iwakura Y & Yoshida H. IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection. J Immunol 2010; 185: 1150-1157.
53. Monteiro AC, Schmitz V, Morrot A, et al. Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. PLoS Pathog 2007; 3: e185.
54. da Matta Guedes PM, Gutierrez FR, Maia FL, et al. IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis 2010; 4: e604.
55. Coelho dos Santos JS, Menezes CA, Villani FN, et al. Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells. Clin Exp Immunol 2010; 162: 528-536.
56. Costa GC, da Costa Rocha MO, Moreira PR, et al. Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis 2009; 199: 451-454.
57. Villani FN, Rocha MO, Nunes Mdo C, et al. Trypanosoma cruzi-induced activation of functionally distinct alphabeta and gammadelta CD4- CD8- T cells in individuals with polar forms of Chagas' disease. Infect Immun 2010; 78: 4421-4430.
58. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ & Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
59. Reis DD, Jones EM, Tostes S Jr, et al. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg 1993; 48: 637-644.
60. Higuchi MD, Ries MM, Aiello VD, et al. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 1997; 56: 485-489.
61. Abel LC, Rizzo LV, Ianni B, et al. Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. J Autoimmun 2001; 17: 99-107.
62. Dutra WO, Gollob KJ, Pinto-Dias JC, et al. Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Scand J Immunol 1997; 45: 74-80.
63. Bahia-Oliveira LM, Gomes JA, Rocha MO, et al. IFN-gamma in human Chagas' disease: protection or pathology? Braz J Med Biol Res 1998; 31: 127-131.
64. Laucella SA, Postan M, Martin D, et al. Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004; 189: 909-918.
65. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G & Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun 2003; 71: 1185-1193.
66. Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL & Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin Infect Dis 2004; 38: 943-950.
67. Pozo D & Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J 2004; 18: 1325-1334.
68. Taub DD. Neuroendocrine interactions in the immune system. Cell Immunol 2008; 252: 1-6.
69. Webster Marketon JI & Glaser R. Stress hormones and immune function. Cell Immunol 2008; 252: 16-26.
70. Corrêa-de-Santana E, Paez-Pereda M, Theodoropoulou M, et al. Hypothalamus-pituitary-adrenal axis during Trypanosoma cruzi acute infection in mice. J Neuroimmunol 2006; 173: 12-22.
71. Filipin Mdel V, Brazao V, Santello FH, Caetano LC, Toldo MP & do Prado JC Jr. Prolactin: does it exert an up-modulation of the immune response in Trypanosoma cruzi-infected rats? Vet Parasitol 2011; 181: 139-145.
72. Perez AR, Silva-Barbosa SD, Berbert LR, et al. Immunoneuroendocrine alterations in patients with progressive forms of chronic Chagas disease. J Neuroimmunol 2011; 235: 84-90.
73. Maifrino LB, Amaral SO, Watanabe I, Liberti EA & De Souza RR. Trypanosoma cruzi: preliminary investigation of NADH-positive and somatostatin-immunoreactive neurons in the myenteric plexus of the mouse colon during the infection. Exp Parasitol 2005; 111: 224-229.
74. Nascimento RD, Martins PR, de Souza Lisboa A, Adad SJ, Morais da Silveira AB & Reis D. An imbalance between substance P and vasoactive intestinal polypeptide might contribute to the immunopathology of megaesophagus after Trypanosoma cruzi infection. Hum Pathol 2013; 44: 269-276.
75. Moreira MD, Brehmer A, de Oliveira EC, et al. Regenerative process evaluation of neuronal subclasses in chagasic patients with megacolon. Hum Immunol 2013; 74: 181-188.
76. da Silveira AB, D'Avila Reis D, de Oliveira EC, et al. Neurochemical coding of the enteric nervous system in chagasic patients with megacolon. Dig Dis Sci 2007; 52: 2877-2883.
77. da Silveira AB, Freitas MA, de Oliveira EC, et al. Substance P and NK1 receptor expression in the enteric nervous system is related to the development of chagasic megacolon. Trans R Soc Trop Med Hyg 2008; 102: 1154-1156.
78. Jabari S, da Silveira AB, de Oliveira EC, et al. Selective survival of calretinin- and vasoactive intestinal peptide containing nerve elements in human chagasic submucosa and mucosa. Cell Tissue Res 2012; 349: 473-481.
79. Jabari S, da Silveira AB, de Oliveira EC, et al. Preponderance of inhibitory versus excitatory intramuscular nerve fibres in human chagasic megacolon. Int J Colorectal Dis 2012; 27: 1181-1189.
80. Correa MV, da Costa Rocha MO, de Sousa GR, et al. Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy. Hum Immunol 2013; 74: 1375-1381.